Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
22.31
-0.04 (-0.18%)
At close: Sep 25, 2026, 4:00 PM EDT
22.31
0.00 (0.00%)
After-hours: Sep 25, 2026, 4:10 PM EDT
Elanco Animal Health Revenue
Elanco Animal Health had revenue of $1.37B in the quarter ending June 30, 2026, with 10.23% growth. This brings the company's revenue in the last twelve months to $5.02B, up 11.95% year-over-year. In the year 2025, Elanco Animal Health had annual revenue of $4.72B with 6.22% growth.
Revenue (ttm)
$5.02B
Revenue Growth
+11.95%
P/S Ratio
2.25
Revenue / Employee
$507,071
Employees
9,900
Market Cap
11.15B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.72B | 276.00M | 6.22% |
| Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
| Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
| Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
| Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
| Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
| Dec 31, 2019 | 3.07B | 4.20M | 0.14% |
| Dec 31, 2018 | 3.07B | 177.80M | 6.15% |
| Dec 31, 2017 | 2.89B | -24.50M | -0.84% |
| Dec 31, 2016 | 2.91B | 4.40M | 0.15% |
| Dec 31, 2015 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
| Amneal Pharmaceuticals | 3.12B |
| Hims & Hers Health | 2.58B |
| Alkermes | 1.67B |
ELAN News
- 3 days ago - Elanco Animal Health Transcript: Bank of America Global Healthcare Conference - Transcripts
- 8 days ago - Elanco to Participate in BofA Securities Global Healthcare Conference 2026 - PRNewsWire
- 10 days ago - Elanco Animal Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 10 days ago - Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care - PRNewsWire
- 14 days ago - Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement - PRNewsWire
- 15 days ago - Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - PRNewsWire
- 4 weeks ago - Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility - PRNewsWire
- 7 weeks ago - Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species - PRNewsWire